Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma

Background There is substantial circumstantial evidence that CD4 lymphocytes have a role in the pathogenesis of chronic asthma. We investigated the efficacy and safety in severe corticosteroid-dependent asthma of a single intravenous infusion of keliximab (IDEC CE9·1), a chimeric monoclonal antibody to CD4. Methods 22 patients were recruited from two asthma clinics. In an ascending-dose design, the first eight patients were assigned 0·5 mg/kg keliximab (six) or placebo (two); the next seven were assigned 1·5 mg/kg (five) or placebo (two); and the last seven were assigned 3·0 mg/kg (five) or placebo (two). Masked data on safety for each dose group were assessed before progression to the next dose. Patients kept a daily symptom diary and measured morning and evening peak expiratory flow (PEF) at home. PEF and forced expiratory volume in 1 s (FEV1) were measured at follow-up clinic visits. Findings Patients given 0·5 mg/kg or 1·5 mg/kg keliximab and placebo recipients did not differ in change from baseline of PEF, FEV1, or symptom score. Those given 3·0 mg/kg keliximab differed significantly from placebo recipients in change in morning PEF (median area under curve [AUC] 445 vs −82·5, p=0·005) and evening PEF (median AUC 548 vs −85, p=0·014). Symptom score showed the same pattern (though differences did not achieve significance), but there was no difference in clinic FEV1. There were no serious adverse effects related to treatment. Two patients had mild exacerbations of eczema and one developed a transient maculopapular rash. All doses of keliximab were associated with a reduction from baseline in CD4 count. Interpretation Our findings raise the possibility that T-cell-directed treatment may be an alternative approach to the treatment of severe asthma.